A Phase 2 interventional study of Tulisokibart and Companion Diagnostic (CDx) in Crohn Disease, sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 37 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Crohn Disease by Merck & Co., Inc — 2 open to participants now, 2 under way, 2 of them phase 3. Crohn Disease · Merck & Co., Inc.
Among the 16 studies in Crohn Disease by Merck & Co., Inc, this one is the only one that started in 2021, is the only one in phase 2, and was the 14th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →2 of the 16 studies in Crohn Disease by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Czechia, France and 4 more countries
Merck Sharp & Dohme LLC · Sites in United States, Australia, Austria and 44 more countries
Ages 16–80
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2021.
This study's enrollment of 55 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 100 across the 5 interventional studies, 245 across the 11 observational. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), one of the names counted as Merck & Co., Inc. Under that name alone:
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Crohn Disease by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of tulisokibart (MK-7240) in participants with moderately to severely active Crohn's Disease.
After the completion of the 12-week Induction Period, eligible participants have the option to enter an Open-label Extension (OLE) Period for up to 170 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the 12-week Induction Period, participants receive tulisokibart administered by intravenous (IV) infusion at 1000 mg at Week 0 and 500 mg at Weeks 2, 6, and 10.
Biological: Tulisokibart · Diagnostic Test: Companion Diagnostic (CDx)
After completing the 12-week Induction Period, eligible participants have the option to enter the OLE Period for up to 170 weeks. Participants are randomized into the OLE Period to receive 100 mg tulisokibart by IV infusion every 4 weeks (q4w). At the discretion of the investigator, participants may titrate up to 250 mg Q4W if disease activity is not adequately controlled.
Biological: Tulisokibart
After completing the 12-week Induction Period, eligible participants have the option to enter the OLE Period for up to 170 weeks. Participants are randomized into the OLE Period to receive 250 mg tulisokibart by IV infusion q4w.
Biological: Tulisokibart
Tulisokibart administered by IV infusion as directed by the protocol
Also known as: PRA023, MK-7240
PRA023 CDx Genotyping Assay
Adverse Events
Number of participants who experienced treatment-emergent adverse events (AEs)
Time frame: Up to approximately 18 weeks
Serious Adverse Events
Number of participants who experienced serious adverse events (SAEs)
Time frame: Up to approximately 18 weeks
Adverse Events Leading to Discontinuation
Number of participants who experienced AEs leading to discontinuation
Time frame: Up to approximately 12 weeks
Endoscopic Improvement
Number of participants achieving induction of endoscopic improvement (decrease in simple endoscopy score for Crohn's disease \[SES-CD\] ≥ 50% from Baseline)
Time frame: Week 12
Clinical Remission
Number of participants achieving clinical remission, as defined by Crohn's disease activity index \[CDAI\] score \< 150
Time frame: Week 12
Endoscopic and Clinical Improvement
Number of participants who achieved a decrease in SES-CD ≥ 50% AND reduction in CDAI ≥ 100 points from Baseline or CDAI\<150
Time frame: Week 12
Number of Participants Achieving Biomarker and Clinical Composite Improvement
Biomarker and clinical composite improvement is defined as a decrease by at least 50% in hsCRP or fecal calprotectin from baseline and a reduction of either CDAI ≥ 100 points from Baseline or CDAI\<150 in subjects with at least one elevated biomarker at baseline.
Time frame: Week 12
Normalization of C-reactive Protein
Number of participants with normalization of hsCRP (as defined by hsCRP \< 5 mg/L), among subjects with elevated concentrations at Baseline, at Week 12
Time frame: Week 12
Normalization of Fecal Calprotectin
Number of participants with normalization of fecal calprotectin (fecal calprotectin \< 250 ug/g), among subjects with elevated concentrations at Baseline, at Week 12
Time frame: Week 12
Clinical Response
Clinical response is defined as either a reduction of either CDAI ≥ 100 points from Baseline or CDAI\<150.
Time frame: Week 12
Two Component Patient-reported Outcome (PRO-2) Remission
Number of subjects with PRO-2 remission (defined as average daily abdominal pain score ≤ 1 point and average daily stool frequency ≤ 3 points with abdominal pain and stool frequency no worse than Baseline) at Week 12.
Time frame: Week 12
Change From Baseline in Simple Endoscopy Score for Crohn's Disease (SES-CD)
Assessment of change in simple endoscopy score for Crohn's Disease (SES-CD) from Baseline. Measure Description: The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
Time frame: Baseline and Week 12
Serum Concentration of Tulisokibart
Blood samples were obtained for PK analysis of the serum concentration of tulisokibart at week 12.
Time frame: Week 12
Number of Participants Positive for Anti-drug Antibody (ADA)
Blood samples were collected for the determination of anti-tulisokibart antibodies based on confirmatory assay. The number of participants with confirmed positive anti-tulisokibart antibodies results at any visit during the study is presented.
Time frame: Up to approximately 12 weeks
Number of Participants With Positive Neutralizing Anti-Bodies (NAB)
Blood samples were collected for the determination of NAB. The number of participants with positive NAB results at any visit during the study is presented.
Time frame: Up to approximately 12 weeks
Eligible participants were allocated to the open-label 12-week Induction Period to receive tulisokibart by intravenous infusion. Eligible participants who completed the Induction Period and responded to tulisokibart treatment may have continued into an optional 170-week Open-label Extension (OLE) Period. Participants who entered the OLE Period were randomized to receive tulisokibart at either 100 mg every 4 weeks (q4w) or 250 mg q4w.
| Milestone | Induction Tulisokibart | OLE Tulisokibart 100 mg | OLE Tulisokibart 250 mg |
|---|---|---|---|
| Started | 55 | 0 | 0 |
| Completed | 49 | 0 | 0 |
| Not completed | 6 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 | 0 |
| Milestone | Induction Tulisokibart | OLE Tulisokibart 100 mg | OLE Tulisokibart 250 mg |
|---|---|---|---|
| Started | 0 | 19 | 18 |
| Completed | 0 | 9 | 2 |
| Not completed | 0 | 10 | 16 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 | 4 |
| Withdrew: Transitioned to a separate long-term extension study | 0 | 5 | 10 |
| Withdrew: Relocated away from the study site | 0 | 1 | 0 |
Number of participants who experienced treatment-emergent adverse events (AEs)
| Participants | Induction Tulisokibart |
|---|---|
| Adverse Events | 44 |
Number of participants who experienced serious adverse events (SAEs)
| Participants | Induction Tulisokibart |
|---|---|
| Serious Adverse Events | 9 |
Number of participants who experienced AEs leading to discontinuation
| Participants | Induction Tulisokibart |
|---|---|
| Adverse Events Leading to Discontinuation | 2 |
Number of participants achieving induction of endoscopic improvement (decrease in simple endoscopy score for Crohn's disease \[SES-CD\] ≥ 50% from Baseline)
| Participants | Induction Tulisokibart |
|---|---|
| Endoscopic Improvement | 13 |
Number of participants achieving clinical remission, as defined by Crohn's disease activity index \[CDAI\] score \< 150
| Participants | Induction Tulisokibart |
|---|---|
| Clinical Remission | 27 |
Number of participants who achieved a decrease in SES-CD ≥ 50% AND reduction in CDAI ≥ 100 points from Baseline or CDAI\<150
| Participants | Induction Tulisokibart |
|---|---|
| Endoscopic and Clinical Improvement | 9 |
Biomarker and clinical composite improvement is defined as a decrease by at least 50% in hsCRP or fecal calprotectin from baseline and a reduction of either CDAI ≥ 100 points from Baseline or CDAI\<150 in subjects with at least one elevated biomarker at baseline.
| Participants | Induction Tulisokibart |
|---|---|
| Number of Participants Achieving Biomarker and Clinical Composite Improvement | 17 |
Number of participants with normalization of hsCRP (as defined by hsCRP \< 5 mg/L), among subjects with elevated concentrations at Baseline, at Week 12
| Participants | Induction Tulisokibart |
|---|---|
| Normalization of C-reactive Protein | 5 |
Number of participants with normalization of fecal calprotectin (fecal calprotectin \< 250 ug/g), among subjects with elevated concentrations at Baseline, at Week 12
| Participants | Induction Tulisokibart |
|---|---|
| Normalization of Fecal Calprotectin | 6 |
Clinical response is defined as either a reduction of either CDAI ≥ 100 points from Baseline or CDAI\<150.
| Participants | Induction Tulisokibart |
|---|---|
| Clinical Response | 37 |
Number of subjects with PRO-2 remission (defined as average daily abdominal pain score ≤ 1 point and average daily stool frequency ≤ 3 points with abdominal pain and stool frequency no worse than Baseline) at Week 12.
| Participants | Induction Tulisokibart |
|---|---|
| Two Component Patient-reported Outcome (PRO-2) Remission | 27 |
Assessment of change in simple endoscopy score for Crohn's Disease (SES-CD) from Baseline. Measure Description: The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
| score on a scale | Induction Tulisokibart |
|---|---|
| Change From Baseline in Simple Endoscopy Score for Crohn's Disease (SES-CD) | -2.6 ± 4.32 |
Blood samples were obtained for PK analysis of the serum concentration of tulisokibart at week 12.
| ng/mL | Induction Tulisokibart |
|---|---|
| Serum Concentration of Tulisokibart | 88199.1 ± 43811.21 |
Blood samples were collected for the determination of anti-tulisokibart antibodies based on confirmatory assay. The number of participants with confirmed positive anti-tulisokibart antibodies results at any visit during the study is presented.
| Participants | Induction Tulisokibart |
|---|---|
| Number of Participants Positive for Anti-drug Antibody (ADA) | 8 |
Blood samples were collected for the determination of NAB. The number of participants with positive NAB results at any visit during the study is presented.
| Participants | Induction Tulisokibart |
|---|---|
| Number of Participants With Positive Neutralizing Anti-Bodies (NAB) | 8 |
Collected over Up to approximately 43 months (duration over which AEs were assessed at the participant level). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction Tulisokibart | 0/55 (0%) | 9/55 (16.4%) | 33/55 (60%) |
| Induction Tulisokibart → OLE Tulisokibart 100 mg | 0/19 (0%) | 4/19 (21.1%) | 17/19 (89.5%) |
| Induction Tulisokibart → OLE Tulisokibart 250 mg | 0/18 (0%) | 4/18 (22.2%) | 16/18 (88.9%) |
| Event | Induction Tulisokibart | Induction Tulisokibart → OLE Tulisokibart 100 mg | Induction Tulisokibart → OLE Tulisokibart 250 mg |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 4/55 | 3/19 | 2/18 |
| Small intestinal obstructionGastrointestinal disorders | 0/55 | 2/19 | 1/18 |
| Diarrhoea infectiousInfections and infestations | 0/55 | 0/19 | 1/18 |
| Transient ischaemic attackNervous system disorders | 0/55 | 0/19 | 1/18 |
| Atrial fibrillationCardiac disorders | 0/55 | 1/19 | 0/18 |
| Small intestinal perforationGastrointestinal disorders | 0/55 | 1/19 | 0/18 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/55 | 1/19 | 0/18 |
| Abdominal painGastrointestinal disorders | 2/55 | 0/19 | 0/18 |
| Anal abscessInfections and infestations | 1/55 | 0/19 | 0/18 |
| COVID-19 pneumoniaInfections and infestations | 1/55 | 0/19 | 0/18 |
| Event | Induction Tulisokibart | Induction Tulisokibart → OLE Tulisokibart 100 mg | Induction Tulisokibart → OLE Tulisokibart 250 mg |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 3/55 | 7/19 | 6/18 |
| Upper respiratory tract infectionInfections and infestations | 2/55 | 5/19 | 3/18 |
| GastroenteritisInfections and infestations | 0/55 | 1/19 | 4/18 |
| VomitingGastrointestinal disorders | 2/55 | 0/19 | 3/18 |
| Urinary tract infectionInfections and infestations | 5/55 | 3/19 | 3/18 |
| COVID-19Infections and infestations | 7/55 | 3/19 | 2/18 |
| HeadacheNervous system disorders | 2/55 | 3/19 | 2/18 |
| Anal fistulaGastrointestinal disorders | 0/55 | 2/19 | 2/18 |
| BronchitisInfections and infestations | 1/55 | 0/19 | 2/18 |
| Clostridium difficile infectionInfections and infestations | 0/55 | 0/19 | 2/18 |
| Age, Customized(Participants) | Induction Tulisokibart |
|---|---|
| Age (years) — 18-44 years | 37 |
| Age (years) — 45-64 years | 13 |
| Age (years) — 65+ years | 5 |
| Sex: Female, Male(Participants) | Induction Tulisokibart |
|---|---|
| Female | 21 |
| Male | 34 |
| Ethnicity (NIH/OMB)(Participants) | Induction Tulisokibart |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 51 |
| Unknown or Not Reported | 3 |
| Race (NIH/OMB)(Participants) | Induction Tulisokibart |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 48 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
| Weight(kg) | Induction Tulisokibart |
|---|---|
| Mean | 77.6 ± 20.6 |
| Duration of Disease (years)(years) | Induction Tulisokibart |
|---|---|
| Mean | 10.29 ± 9.27 |
| Baseline Crohn's disease activity index (CDAI) Score(score) | Induction Tulisokibart |
|---|---|
| Mean | 317.9 ± 67.2 |
| Number of Prior Exposure to Biologic Therapy(Participants) | Induction Tulisokibart |
|---|---|
| Biologic Naive | 16 |
| 1 Prior Biologic | 10 |
| 2 Prior Biologics | 10 |
| >=3 Prior Biologics | 19 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jul 2021 to primary completion in Sep 2022, 13 months.
Results were first posted in Nov 2023, 1 year 1 month after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 13 months is below that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tulisokibart
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) →